- Home
- ICON vs SXTP Comparison
ICON vs SXTP Comparison
Compare ICON & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICON | SXTP |
|---|---|---|
| Founded | 2023 | 2010 |
| Country | Greece | United States |
| Employees | N/A | 3 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ICON | SXTP |
|---|---|---|
| Price | $1.03 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $22.50 | $17.60 |
| AVG Volume (30 Days) | 128.6K | ★ 2.4M |
| Earning Date | 02-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 100.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.33 | $48.39 |
| Revenue Next Year | $23.70 | $84.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.34 |
| 52 Week High | $4.23 | $8.62 |
Technical Indicators
Market Signals| Indicator | ICON | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 44.48 |
| Support Level | $0.69 | $1.27 |
| Resistance Level | $2.34 | $2.58 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 79.27 | 43.51 |
Price Performance
Historical ComparisonAbout ICON Icon Energy Corp.
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.